The European Medicines Agency has warned about the possibility of a cumulative impact of the COVID-19 outbreak if drug supply problems caused by the coronavirus add to existing product shortages in the EU.
The agency is also trying to identify products that incorporate Chinese active pharmaceutical ingredients and could be at risk of shortages if the manufacture and supply